Pavurutamab

帕沃瑞妥单抗

Report date: 2026/03/19 16:52:49

Base Information

Drug NamePavurutamab

Drug Alias NameAMG-701

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-BCMAT cell surface glycoprotein CD3 stimulants

TargetsB-cell maturation proteinT cell surface glycoprotein CD3

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesNetherlands +[7]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesAmgen Inc

China Registration ClassN/A

Develop Information

Active CompaniesBeOne Medicines Ltd

Inactive CompaniesAmgen Inc

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A